What is FineHeart?
FineHeart operates at the intersection of advanced engineering and life-saving medical intervention. The company is primarily recognized for the development of the ICOMS, an intracardiac pump designed to augment native ejection fraction in patients with severe heart failure. By providing a minimally invasive alternative to traditional cardiac assist devices, FineHeart addresses a significant unmet need in the global healthcare market. The firm's strategic positioning is bolstered by its focus on high-precision medical hardware, targeting both healthcare providers and patients who require effective, long-term solutions for chronic cardiac conditions. Through its commitment to clinical excellence, FineHeart is establishing itself as a pivotal player in the future of heart failure management.
How much funding has FineHeart raised?
FineHeart has raised a total of $30.9M across 2 funding rounds:
Series A
$7.2M
Series B
$23.7M
Series A (2016): $7.2M with participation from Broadview Ventures, Galia Gestion, and Sofimac
Series B (2021): $23.7M led by Doliam's Companies, Lauak Group, and Verve Ventures
Key Investors in FineHeart
Broadview Ventures
Broadview Ventures is an impact-focused investment firm specializing in cardiovascular disease and stroke, dedicated to accelerating the development of innovative medical technologies.
Galia Gestion
Galia Gestion is a prominent French private equity firm that supports regional SMEs and mid-sized enterprises with a strong commitment to ESG-integrated investment strategies.
Sofimac
Sofimac Innovation is a specialized investment firm that provides essential resources and financial backing to startups and projects focused on technological advancement.
What's next for FineHeart?
Looking ahead, the infusion of $23.7M positions FineHeart to transition from its current development phase toward broader clinical validation and eventual commercialization. The company is expected to leverage this capital to scale its manufacturing capabilities and expand its regulatory footprint across international markets. By maintaining a focus on the ICOMS platform, FineHeart aims to solidify its market position as a leader in cardiac assist technology. Future strategic initiatives will likely involve deepening partnerships with major healthcare institutions and continuing to optimize the device for diverse patient profiles, ensuring that the company remains at the forefront of the MedTech innovation cycle.
See full FineHeart company page
